GLP-1semaglutidetirzepatideobesityguidelines

Turkish cardiology journal issues prescribing guide for GLP-1 and GIP/GLP-1 agonists

The clinician-oriented framework covers eligibility, baseline workup, gradual titration, side-effect management and long-term weight maintenance.

By Maren Holt · Senior Reporter, GLP-1

Oct 4 20:00 ETSource: Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir

The wire

01A practical guideline in Turk Kardiyoloji Dernegi arsivi lays out a step-by-step approach to patient selection, contraindication screening, counseling, dose titration and follow-up for obesity pharmacotherapy.
02It also summarizes day-to-day prescribing differences between semaglutide and tirzepatide, useful for clinicians fielding requests for incretin therapy.
03It is a narrative practice guide rather than new trial data, and reflects one national society's framing of the cardiometabolic evidence.

From the source

Practical Considerations for the Use of GLP-1 and Dual GIP/GLP-1 Receptor Agonists in Obesity: A Clinician-Oriented Guide
Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir · 2026 Oct 5 · Alp GT, Gökçay Canpolat A et al.

Read at pubmed.ncbi.nlm.nih.gov

Source URL https://pubmed.ncbi.nlm.nih.gov/42832185/